Angiogenesis in brain tumours

Rakesh K. Jain; Emmanuelle di Tomaso; Dan G. Duda; Jay S. Loeffler; A. Gregory Sorensen; Tracy T. Batchelor

doi:10.1038/nrn2175

journal article Aug 01, 2007

Angiogenesis in brain tumours

Rakesh K. Jain

Emmanuelle di Tomaso Dan G. Duda

Jay S. Loeffler A. Gregory Sorensen Tracy T. Batchelor

Nature Reviews Neuroscience Vol. 8 No. 8 pp. 610-622 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/nrn2175

Topics

No keywords indexed for this article. Browse by subject →

References

150

[1]

Wong, E. T. et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 17, 2572–2578 (1999). 10.1200/jco.1999.17.8.2572

[2]

Stupp, R. et al. Changing paradigms — an update on the multidisciplinary management of malignant glioma. Oncologist 11, 165–180 (2006). 10.1634/theoncologist.11-2-165

[3]

van de Beek, D. Brain teasing effect of dexamethasone. Lancet Neurol. 6, 203–204 (2007). 10.1016/s1474-4422(07)70041-8

[4]

Kleihues, P., Burger, P. C. & Scheithauer, B. W. in Histological Typing of Tumours of the Central Nervous System 2nd edn (ed. Sobin, L. H.) 1–105 (Springer, Berlin, 1993). 10.1007/978-3-642-84988-6

[5]

Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971). 10.1056/nejm197108122850711

[6]

Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nature Rev. Drug Discov. 6, 273–286 (2007). Reference 5 is the seminal paper that led to search for anti-angiogenic therapy for cancer. Reference 6 illustrates how this hypothesis has influenced treatment of cancer and other diseases. 10.1038/nrd2115

[7]

Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nature Clin. Pract. Oncol. 3, 24–40 (2006). A critical review of progress and outstanding issues in anti-angiogenic therapy of cancer in patients. 10.1038/ncponc0403

[8]

Purow, B. & Fine, H. A. Progress report on the potential of angiogenesis inhibitors for neuro-oncology. Cancer Invest. 22, 577–587 (2004). 10.1081/cnv-200027141

[9]

Pope, W. B., Lai, A., Nghiemphu, P., Mischel, P. & Cloughesy, T. F. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66, 1258–1260 (2006). 10.1212/01.wnl.0000208958.29600.87

[10]

Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

Rakesh K. Jain

Nature Medicine 2001 10.1038/nm0901-987

[11]

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

Rakesh K. Jain

Science 2005 10.1126/science.1104819

[12]

Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1 and matrix metalloproteinases. Cancer Cell 6, 553–563 (2004). First pre-clinical evidence of vascular normalization in an orthotopic model of glioma in mice. This paper also provides the molecular mechanisms of vascular normalization and demonstrates that the outcome of radiation therapy is best when given during the window of normalization.

[13]

Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007). First clinical evidence of a window of vascular normalization in recurrent glioblastoma induced by an anti-angiogenic agent. Also demonstrates the benefits of normalization in alleviating oedema and identifies potential blood and imaging biomarkers. 10.1016/j.ccr.2006.11.021

[14]

Vredenburgh, J. J. et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253–1259 (2007). 10.1158/1078-0432.ccr-06-2309

[15]

Fidler, I. J., Yano, S., Zhang, R. D., Fujimaki, T. & Bucana, C. D. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 3, 53–57 (2002). An excellent review of vascular biology of brain metastases. 10.1016/s1470-2045(01)00622-2

[16]

Neuwelt, E. A. Mechanisms of disease: the blood–brain barrier. Neurosurgery 54, 131–140 (2004). 10.1227/01.neu.0000097715.11966.8e

[17]

Palmieri, D., Chambers, A. F., Felding-Habermann, B., Huang, S. & Steeg, P. S. The biology of metastasis to a sanctuary site. Clin. Cancer Res. 13, 1656–1662 (2007). 10.1158/1078-0432.ccr-06-2659

[18]

Yuan, F. et al. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res. 54, 4564–4568 (1994).

[19]

Hobbs, S. K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607–4612 (1998). 10.1073/pnas.95.8.4607

[20]

Monsky, W. L. et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 59, 4129–4135 (1999).

[21]

Fukumura, D. et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61, 6020–6024 (2001).

[22]

Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002). References 18–22 are key papers on the structure and function of tumour vasculature in orthotopic models of primary and metastatic brain tumours in mice. 10.1038/416279b

[23]

Bullitt, E. et al. Vessel tortuosity and brain tumor malignancy: a blinded study. Acad. Radiol. 12, 1232–1240 (2005). 10.1016/j.acra.2005.05.027

[24]

Deeken, J. F. & Loscher, W. The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 13, 1663–1674 (2007). 10.1158/1078-0432.ccr-06-2854

[25]

Plate, K. H. & Mennel, H. D. Vascular morphology and angiogenesis in glial tumors. Exp. Toxicol. Pathol. 47, 89–94 (1995). 10.1016/s0940-2993(11)80292-7

[26]

Rampling, R., Cruickshank, G., Lewis, A., Fitzsimmon, S. & Workman, P. Direct measurment of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 29, 427–431 (1994). 10.1016/0360-3016(94)90432-4

[27]

Valk, P. E., Mathis, C. A., Prados, M. D., Gilbert, J. C. & Budinger, T. F. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J. Nucl. Med. 33, 2133–2137 (1992).

[28]

Guo, P. et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol. 162, 1083–1093 (2003). 10.1016/s0002-9440(10)63905-3

[29]

Zagzag, D. et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp. Neurol. 159, 391–400 (1999). 10.1006/exnr.1999.7162

[30]

Kleihues, P. & Cavenee, W. K. Pathology and Genetics of Tumours of the Nervous System (International Agency for Research on Cancer, Lyon, 2000).

[31]

Jain, R. K. The next frontier of molecular medicine: delivery of therapeutics. Nature Med. 4, 655–657 (1998). 10.1038/nm0698-655

[32]

Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nature Rev. Cancer 2, 266–276 (2002). A comprehensive review of microscopy techniques to measure molecular, cellular, anatomical and physiological parameters of tumour vessels in live animals. 10.1038/nrc778

[33]

Monsky, W. L. et al. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin. Cancer Res. 8, 1008–1013 (2002).

[34]

Jain, R. K., Tong, R. T. & Munn, L. L. Effect of vascular normalization by anti-angiogenic therapy on interstitial hypertension, peri-tumor edema and lymphatic metastasis: insights from a mathematical model. Cancer Res. 67, 2729–2735 (2007). 10.1158/0008-5472.can-06-4102

[35]

Wolf, R. L. et al. Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J. Magn. Reson. Imaging 22, 475–482 (2005). 10.1002/jmri.20415

[36]

Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation

Gabriel Helmlinger, Fan Yuan, Marc Dellian et al.

Nature Medicine 1997 10.1038/nm0297-177

[37]

Angiogenesis in cancer and other diseases

Peter Carmeliet, Rakesh K. Jain

Nature 2000 10.1038/35025220

[38]

Dvorak, H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368–4380 (2002). 10.1200/jco.2002.10.088

[39]

Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581–611 (2004). References 38 and 39 provide excellent overviews of VEGF biology and its role in angiogenesis. 10.1210/er.2003-0027

[40]

Fukumura, D., Kashiwagi, S. & Jain, R. K. The role of nitric oxide in tumour progression. Nature Rev. Cancer 6, 521–534 (2006). 10.1038/nrc1910

[41]

Tumor Induction of VEGF Promoter Activity in Stromal Cells

Dai Fukumura, Ramnik Xavier, Takeyuki Sugiura et al.

Cell 1998 10.1016/s0092-8674(00)81731-6

[42]

Boucher, Y., Salehi, H., Witwer, B., Harsh, G. R. & Jain, R. K. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer 75, 829–836 (1997). 10.1038/bjc.1997.148

[43]

Jain, R. K. Barriers to drug delivery in solid tumors. Sci. Am. 271, 58–65 (1994). 10.1038/scientificamerican0794-58

[44]

DiResta, G. R. et al. 'Artificial lymphatic system': a new approach to reduce interstitial hypertension and increase blood flow, pH and pO2 in solid tumors. Ann. Biomed. Eng. 28, 543–555 (2000). 10.1114/1.295

[45]

Fukumura, D. et al. Tumor-necrosis-factor α-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res. 55, 4824–4829 (1995).

[46]

Melder, R. J. et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nature Med. 2, 992–997 (1996). 10.1038/nm0996-992

[47]

Melder, R. J., Salehi, H. A. & Jain, R. K. Interaction of activated natural killer cells with normal and tumor vessels in cranial windows in mice. Microvasc. Res. 50, 35–44 (1995). 10.1006/mvre.1995.1036

[48]

Holash, J. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994–1998 (1999). 10.1126/science.284.5422.1994

[49]

Leenders, W. P., Kusters, B. & de Waal, R. M. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 9, 83–87 (2002). 10.1080/10623320212006

[50]

Padera, T. P. et al. Pathology: cancer cells compress intratumour vessels. Nature 427, 695 (2004). 10.1038/427695a

Showing 50 of 150 references

Cited By

1,150

Conventional and Advanced Magnetic Resonance Imaging Assessment of Non-Enhancing Peritumoral Area in Brain Tumor

Elisa Scola, Guido Del Vecchio · 2023

Cancers

Differentiation of Glioblastoma from Brain Metastasis: Qualitative and Quantitative Analysis Using Arterial Spin Labeling MR Imaging

Leonard Sunwoo, Tae Jin Yun · 2016

PLoS ONE

A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas

Trent R. Hummel, Ralph Salloum · 2015

Journal of Neuro-Oncology

Angiogenesis and Angiogenic Tyrosine Kinase Receptor Expression in Pediatric Brain Tumors

József Virág, István Kenessey · 2013

Pathology & Oncology Research

Neo-vascularization of the stroke cavity by implantation of human neural stem cells on VEGF-releasing PLGA microparticles

Ellen Bible, Omar Qutachi · 2012

Biomaterials

Hypoxic Cell Waves Around Necrotic Cores in Glioblastoma: A Biomathematical Model and Its Therapeutic Implications

Alicia Martínez-González, Gabriel F. Calvo · 2012

Bulletin of Mathematical Biology

Cellular characterization of the peritumoral edema zone in malignant brain tumors

Tobias Engelhorn, Nic E. Savaskan · 2009

Cancer Science

Metrics

1,150

Citations

150

References

Details

Published: Aug 01, 2007
Vol/Issue: 8(8)
Pages: 610-622
License: View

Authors

1Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts and

Tracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason,...

T

Tracy T. Batchelor

Cite This Article

Rakesh K. Jain, Emmanuelle di Tomaso, Dan G. Duda, et al. (2007). Angiogenesis in brain tumours. Nature Reviews Neuroscience, 8(8), 610-622. https://doi.org/10.1038/nrn2175

Angiogenesis in brain tumours

You May Also Like